Login to Your Account

EMA's SME Office Highlights Positive Drug Approval Trends

By Nuala Moran
Staff Writer

Wednesday, February 27, 2013
LONDON – Biotechs registered with the SME (small- and medium-sized enterprise) Office of the European Medicines Agency (EMA) have seen consistent improvements in the success rate of applications for marketing approvals, according to a report analyzing activity in the seven years since the office was set up in 2005.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription